Dendreon (DNDN)

Add a New Bulls Reason Company: Dendreon (DNDN) Current price: Headline: (100 character max) Analysis: Cancel 93% agree 31 votes   U.S. health regulators amend trial design of Provenge Top Contributor: Andrew Horowitz | Created when NASDAQ:DNDN was $5.55 | Edit | History FDA has agreed to an amended Special Protocol Assessment for the Phase 3 IMPACT clinical trial of PROVENGE. In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the IMPACT trial to amend the Biologics License Application for licensure of PROVENGE. However, a real result has yet to materialize and change to the FDA position, which is not contained in this news item. While it may show some level of advancement, it may be a good idea to watch for further results. (100 character max) Cancel 66% agree 3 votes   Strangle DNDN Top Contributor: Rob Tweeddale | Created when NASDAQ:DNDN was $35.53 | Edit | History I like going long the May 40 Calls and May 30 Puts. This stock will react to the FDA action on Provenge in May. PROVENGE is Dendreon's investigational product candidate for men with advanced prostate cancer and may represent the first in a new class of active cellular immunotherapies (ACIs) specifically designed to engage the patient's own immune system against cancer. PROVENGE and other ACIs are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.